{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-017856","form_type":"8-K","ticker":"STIM","cik":"0001227636","company_name":"Neuronetics, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.460893+00:00","generated_at":"2026-06-08T13:39:52.261299+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Neuronetics Q3 revenue $17.9M (+8% YoY); net loss $(9.4)M; narrows FY 2023 guidance","bullets":["Revenue $17.9M (+8% YoY); record US treatment session revenue $13.1M (+10% YoY).","Gross margin 65.8% (down from 78.4%) due to $1.9M inventory write-off; adjusted 77.3%.","Net loss $(9.4)M or $(0.33)/share vs $(7.6)M or $(0.28)/share last year.","Drew down remaining $22.5M from SLR credit facility; cash $35.8M vs $70.3M at Dec 31, 2022.","FY 2023 revenue guidance narrowed to $70-72M; Q4 revenue expected $19-21M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-017856","json":"https://secwatch.observer/filing/0001558370-23-017856.json","markdown":"https://secwatch.observer/filing/0001558370-23-017856.md","text":"https://secwatch.observer/filing/0001558370-23-017856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1227636/000155837023017856/0001558370-23-017856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1227636/000155837023017856/stim-20231107x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T13:39:52.261299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85911bc221eabce66c545876d5ca1c01940c8e89","claim":"Neuronetics, Inc. reported the three months ended September 30, 2023 results: revenue $17.9 million, net income $(9.4) million, EPS $(0.33) per share.","evidence_excerpt":"therapies in the world, today announced its financial and operating results for the third quarter of 2023. Third Quarter 2023 Highlights ● Third quarter 2023 revenue of $17.9 million, an increase of 8% over the third quarter of 2022 ● Record U.S. treatment session revenue of $13.1 million ● Shipped 43 NeuroStar systems ​ Recent Operational Highlights ●","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1227636/000155837023017856/0001558370-23-017856-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2023"},{"label":"Revenue","value":"$17.9 million"},{"label":"Net income","value":"$(9.4) million"},{"label":"EPS","value":"$(0.33) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}